Pfizer’s drug Chantix (varenicline) for smoking cessation has been linked to a few reports of suicidal thoughts and aggressive and errative behavior.
The United States Food and Drug Administration (FDA) is notifying healthcare professionals regarding these potential side effects.
New onset of depression, suicidal thoughts and changes in emotions and behavior have been reported within days or weeks of initiating treatment with Chantix.
Smoking cessation has been reported to be linked to exacerbation of underlying psychiatric illness due to nicotine withdrawal symptoms; therefore, the precise link between Chantix and depressive mood is not clear.
The FDA is asking healthcare providers to monitor patients who are taking Chantix for behavior and mood changes. As well, the FDA has reported that Chantix may be associated with drowsiness.
© 1998-2007 OncoEd.com All Rights Reserved.
These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.
Patient Home
